Recent data show that B cells and plasma cells located in tumours or in tumour-draining
lymph nodes can have important roles in shaping antitumour immune responses. In tumour …

MM cells express high levels of CD38, while CD38 is expressed at relatively low levels on
normal lymphoid and myeloid cells, and in some non-hematopoietic tissues. This expression …

Checkpoint blockade with antibodies specific for cytotoxic T lymphocyte–associated protein
(CTLA)-4 or programmed cell death 1 (PDCD1; also known as PD-1) elicits durable tumor …

Mobilization of the T-cell response against cancer has the potential to achieve long-lasting
cures. However, it is not known how to harness antigen-presenting cells optimally to achieve …

Dendritic cells (DCs) and macrophages use various receptors to recognize foreign antigens
and to receive feedback control from adaptive immune cells. Although it was long believed …

Innate pattern recognition receptor agonists, including Toll-like receptors (TLRs), alter the
tumor microenvironment and prime adaptive antitumor immunity. However, TLR agonists …

In addition to their role in binding antigen, antibodies can regulate immune responses
through interacting with Fc receptors (FcRs). In recent years, significant progress has been …

▪ Abstract Dendritic cells (DCs) have several functions in innate and adaptive immunity. In
addition, there is increasing evidence that DCs in situ induce antigen-specific …

Purpose: Although rituximab is now routinely used in the treatment of B-cell non-Hodgkin's
lymphoma, the mechanism of its antitumor effect is not clear. One potential mechanism of …

Anti-HER2/neu antibody therapy is reported to mediate tumor regression by interrupting
oncogenic signals and/or inducing FcR-mediated cytotoxicity. Here, we demonstrate that the …